StreetInsider.com News Articles

Pacific Bay Weaver Lake Rock Sample Returns 0.78 Ounces per Ton Gold

Tue, 06 Oct 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or the "Company") reports that the Company has received assay results from a program of exploration carried out atit's Weaver Lake Gold Property in southwestern BC, including a grab sample of a quartz vein that returned 26.7 parts per million (ppm) gold (0.78 opt Au) and 1,350 ppm Silver (39.4 opt Ag). The sample was taken approximately 130 metres east from the interpreted main vein system that was the target of past drilling and underground workings. Many other rock, soil and silt samples

Pacific Bay Weaver Lake Rock Sample Returns 0.78 Ounces per Ton Gold

Tue, 06 Oct 2026 08:00:00 -0400

Pacific Bay Weaver Lake Rock Sample Returns 0.78 Ounces per Ton Gold

Tue, 06 Oct 2026 08:00:00 -0400

Pacific Bay Weaver Lake Rock Sample Returns 0.78 Ounces per Ton Gold

Tue, 06 Oct 2026 08:00:00 -0400

Form SCHEDULE 13G PSYENCE BIOMEDICAL LTD. Filed by: AdvisorShares Trust

Mon, 05 Oct 2026 09:41:00 -0400

si-local-file:///var/storage/secattach/20261005/27146869.html

Psyence BioMed unit signs ibogaine manufacturing deal in Texas

Mon, 05 Oct 2026 07:03:13 -0400

Psyence Biomedical Ltd. (Nasdaq: PBM) announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), has entered into a manufacturing services agreement with Benuvia Operations, LLC to produce pharmaceutical-grade ibogaine active pharmaceutical ingredient (API) under current Good Manufacturing Practice standards.

Benuvia operates an approximately 83,000-square-foot pharmaceutical manufacturing facility in Round Rock, Texas, registered with the U.S. Drug Enforcement Administration (DEA). According to Benuvia, the company currently holds approximately half of the U.S. aggregate production quota for ibogaine. Benuvia is advancing applications with the DEA for the import permit and procurement quota required for the planned production.

The manufacturing agreement builds on

Form 6-K PSYENCE BIOMEDICAL LTD. For: Oct 05

Mon, 05 Oct 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20261005/27145435.html

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Mon, 05 Oct 2026 07:00:00 -0400

Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program

HIGHLIGHTS

Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”)
Benuvia operates an 83,000-square-foot, DEA-registered controlled-substance manufacturing facility in Round Rock, Texas, with capabilities spanning development through commercial-scale production
Partnership is intended to connect TIRC’s planned exclusive U.S. access to PsyLabs’ pharmaceutical-grade ibogaine under TIRC’s previously announced binding term sheet with PsyLabs, with U.S.-based

Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine

Mon, 05 Oct 2026 07:00:00 -0400

Partnership intended to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine as TIRC advances its planned U.S. development program
HIGHLIGHTS

Texas Ibogaine Research Corporation (“TIRC”), the wholly-owned Texas subsidiary of Psyence BioMed, enters manufacturing partnership with Benuvia Operations, LLC for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient (“API”)
Benuvia operates an 83,000-square-foot, DEA-registered controlled-substance manufacturing facility in Round Rock, Texas, with capabilities spanning development through commercial-scale production
Partnership is intended to connect TIRC’s planned exclusive U.S. access to PsyLabs’ pharmaceutical-grade ibogaine under TIRC’s previously announced binding term sheet with PsyLabs, with U.S.-based

Psyence BioMed unit signs ibogaine license term sheet with PsyLabs

Mon, 28 Sep 2026 07:03:03 -0400

Psyence Biomedical Ltd. (Nasdaq: PBM) announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), has entered into a binding term sheet with Psyence Labs Ltd. (PsyLabs) for an exclusive license, supply and wholesale distribution arrangement covering pharmaceutical-grade ibogaine in the United States.
Under the term sheet, PsyLabs will grant TIRC exclusive rights to its know-how, trade secrets, cultivation, extraction and processing methods, and technical and regulatory information related to its pharmaceutical-grade ibogaine hydrochloride. PsyLabs will serve as TIRC's exclusive ibogaine supplier, and TIRC will act as PsyLabs' exclusive U.S. wholesaler and distributor. PsyLabs retains all rights outside the United

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Mon, 28 Sep 2026 07:00:00 -0400

Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (“TIRC”), has entered into a binding term sheet with Psyence Labs Ltd. (“PsyLabs”) under which PsyLabs will grant TIRC an exclusive license, supply and wholesale distribution arrangement for PsyLabs’ pharmaceutical-grade ibogaine in the United States. The term sheet is binding on the

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Mon, 28 Sep 2026 07:00:00 -0400

Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement
NEW YORK, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) today announced that its wholly-owned Texas subsidiary, Texas Ibogaine Research Corporation (“TIRC”), has entered into a binding term sheet with Psyence Labs Ltd. (“PsyLabs”) under which PsyLabs will grant TIRC an exclusive license, supply and wholesale distribution arrangement for PsyLabs’ pharmaceutical-grade ibogaine in the United States. The term sheet is binding on the

Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 28

Mon, 28 Sep 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260928/27109891.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 23

Wed, 23 Sep 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260923/27093193.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 23

Wed, 23 Sep 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260923/27093193.html

Psyence BioMed invests up to $5M in PsyLabs, forms Texas unit

Wed, 23 Sep 2026 07:00:55 -0400

Psyence Biomedical Ltd. (Nasdaq: PBM) announced it has agreed to invest up to $5 million in Psyence Labs Ltd. (PsyLabs) and enter a reciprocal share exchange valued at approximately $9 million on each side, according to a company statement.
Psyence BioMed has irrevocably committed to $2.4 million of the investment, covering 936 PsyLabs ordinary shares at $2,564 per share, based on a pre-money equity valuation of PsyLabs of $54 million. The remaining up to $2.6 million is a backstop commitment in two tranches of up to $1.3 million each, subject to milestones and other conditions. Unfunded milestone tranches will lapse if

Psyence BioMed invests up to $5M in PsyLabs, forms Texas unit

Wed, 23 Sep 2026 07:00:55 -0400

Psyence Biomedical Ltd. (Nasdaq: PBM) announced it has agreed to invest up to $5 million in Psyence Labs Ltd. (PsyLabs) and enter a reciprocal share exchange valued at approximately $9 million on each side, according to a company statement.
Psyence BioMed has irrevocably committed to $2.4 million of the investment, covering 936 PsyLabs ordinary shares at $2,564 per share, based on a pre-money equity valuation of PsyLabs of $54 million. The remaining up to $2.6 million is a backstop commitment in two tranches of up to $1.3 million each, subject to milestones and other conditions. Unfunded milestone tranches will lapse if

Psyence BioMed Announces Strategic Ibogaine Investment

Wed, 23 Sep 2026 07:00:00 -0400

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange

Highlights

The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD).
Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.
Psyence BioMed has agreed to invest up to US$5 million in PsyLabs, of which US$2.4 million has been committed, to support scientific development and pharmaceutical-grade manufacturing capabilities relevant to the planned U.S. program.
Psyence BioMed and PsyLabs have

Psyence BioMed Announces Strategic Ibogaine Investment

Wed, 23 Sep 2026 07:00:00 -0400

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange

Highlights

The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD).
Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.
Psyence BioMed has agreed to invest up to US$5 million in PsyLabs, of which US$2.4 million has been committed, to support scientific development and pharmaceutical-grade manufacturing capabilities relevant to the planned U.S. program.
Psyence BioMed and PsyLabs have

Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 14

Mon, 14 Sep 2026 07:34:00 -0400
si-local-file:///var/storage/secattach/20260914/27055419.html

Form 6-K PSYENCE BIOMEDICAL LTD. For: Sep 14

Mon, 14 Sep 2026 07:34:00 -0400
si-local-file:///var/storage/secattach/20260914/27055419.html

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Mon, 14 Sep 2026 07:00:00 -0400

Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity
HIGHLIGHTS

Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development
Positioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangements
Designed to coordinate supply, manufacturing, regulatory and potential clinical development activities through a single U.S. entity with U.S.-based partners

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, today

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Mon, 14 Sep 2026 07:00:00 -0400

Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity
HIGHLIGHTS

Texas-based company established as dedicated U.S. vehicle for regulated ibogaine development
Positioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangements
Designed to coordinate supply, manufacturing, regulatory and potential clinical development activities through a single U.S. entity with U.S.-based partners

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, today

Form F-3 PSYENCE BIOMEDICAL LTD.

Wed, 26 Aug 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260826/26976726.html

Form F-3 PSYENCE BIOMEDICAL LTD.

Wed, 26 Aug 2026 06:02:00 -0400
si-local-file:///var/storage/secattach/20260826/26976726.html